Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Csf1R (Colony Stimulating Factor 1 Receptor, Csf-1R, Csf-1-R, Macrophage Colonystimulating Factor 1 Receptor, C-Fms, Fms, Cd115)), Humanized Monoclonal Antibody
Malignant Ovarian Brenner Tumor
Explore 1 assets in Malignant Ovarian Brenner Tumor →Floatz Rating
CCC49/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
34Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02923739CT.gov Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Ovarian Brenner Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Csf1R (Colony Stimulating Factor 1 Receptor, Csf-1R, Csf-1-R, Macrophage Colonystimulating Factor 1 Receptor, C-Fms, Fms, Cd115)), Humanized Monoclonal Antibody (this asset) | M.D. Anderson Cancer Center | P2 | CCC · 49 |
| Carboplatin | M.D. Anderson Cancer Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | BB |
| Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter | Mayo Clinic | P1/2 | CCC |
Other indications for Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Csf1R (Colony Stimulating Factor 1 Receptor, Csf-1R, Csf-1-R, Macrophage Colonystimulating Factor 1 Receptor, C-Fms, Fms, Cd115)), Humanized Monoclonal Antibody
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fallopian Tube Adenocarcinoma | — | P2 | CCC · 49 |
| Fallopian Tube Clear Cell Adenocarcinoma | — | P2 | CCC · 49 |
| Fallopian Tube Endometrioid Adenocarcinoma | — | P2 | CCC · 49 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1-Kappa, Anti-(Homo Sapiens Csf1R (Colony Stimulating Factor 1 Receptor, Csf-1R, Csf-1-R, Macrophage Colonystimulating Factor 1 Receptor, C-Fms, Fms, Cd115)), Humanized Monoclonal Antibody in Malignant Ovarian Brenner Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-kappa-anti-homo-sapiens-csf1r-colony-stimulating-factor-1-receptor-csf-1r-csf-1-r-macrophage-colonystimulating-factor-1-receptor-c-fms-fms-cd115-humanized-monoclonal-antibody-malignant-ovarian-brenner-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →